+Follow
JohnDee
No personal profile
2
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
JohnDee
2021-12-26
Ok
The Fed Has Created the Monster Market: What's in Store for 2022?
JohnDee
2021-12-26
Ok
Sorry, the original content has been removed
JohnDee
2021-12-26
Test
3 Best Buffett Stocks to Buy for the Long Haul
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4097303038105650","uuid":"4097303038105650","gmtCreate":1639336001388,"gmtModify":1639336001388,"name":"JohnDee","pinyin":"johndee","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9009952313,"gmtCreate":1640468048467,"gmtModify":1676533521758,"author":{"id":"4097303038105650","authorId":"4097303038105650","name":"JohnDee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097303038105650","authorIdStr":"4097303038105650"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009952313","repostId":"1168664020","repostType":4,"repost":{"id":"1168664020","kind":"news","pubTimestamp":1640339173,"share":"https://ttm.financial/m/news/1168664020?lang=en_US&edition=fundamental","pubTime":"2021-12-24 17:46","market":"us","language":"en","title":"The Fed Has Created the Monster Market: What's in Store for 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1168664020","media":"Realmoney","summary":"The year 2021 should be labeled as the one that confounded even the most experienced of investors. T","content":"<p>The year 2021 should be labeled as the one that confounded even the most experienced of investors. Two years after the pandemic where the global central banks flushed the market with unimaginable liquidity in a short period of time to boost an economy that came to a grinding halt, one wonders why the U.S. central bank is still adding net liquidity to the market today, albeit at a slower pace. The Fed's mantra all throughout 2021 has been that \"inflation is transitory.\" But up until recently, when inflation is seen in everything from milk, coffee, rents, lumber, gas, construction, steel... to anything consumer related, even the Fed cannot use this word with a straight face. Using the word transitory loosely can still work if the horizon is anywhere from three months to two years. It seems the bond and rates markets have now forced the hand of the Fed to realize that inflation is certainly not transitory and they need to do something about it.</p>\n<p>The last two years has seen an \"everything bubble.\" Whether we like to believe it or not, all asset classes have risen with the same tide that the Fed created via its liquidity injection, some just a bit more based on beta and leverage. Many fund managers can use the word \"alpha\" to justify their returns, but in short, this Fed liquidity has distorted a host of asset prices and taking some of the larger ones way beyond their own fundamental value given what real yields and rates had done. A good example is the ARK Next Generation Internet ETF (ARKW) and racy tech growth stocks, after rallying in excess of 100%+, they have all now fallen over 50%+ the past few months, when the fundamental picture has not changed.</p>\n<p>And the simple reason is that liquidity is getting less and less in the market as the Fed is slowing down its asset purchases. Most emerging markets central banks and some developed ones have started raising rates, yet the Fed is still buying up to $90B-$100B of assets each month, two years after the pandemic. This at a time when jobless claims are at lows and the economy has recovered close to pre-pandemic levels from the demand side, if not from the employment side. The Fed's target for QE was to get employment back to pre Covid levels, but that goal post is much further now as participation rate has lagged. A lot of people have permanently retired from the workforce and this is something that the Fed is realizing just now.</p>\n<p>The latest FOMC meeting presided by the Fed announced that they would reduce their asset purchases even more aggressively by $30B per month instead of $15B. At this rate, the Fed will end its QE around March 2022. The bigger question now is how soon and how fast will the Fed start to raise rates? The market is pricing in about three rate hikes just in 2022 alone. If supply chain shortages persist, inflation is not expected to come down any time soon. As we enter 2022, we are entering an economy that is robust but at risk of plateauing post the liquidity induced demand surge, and with heightened inflation not seen since the 1980s! The year over year CPI rate is averaging between 6%-7% now, and it is at an alarmingly uncomfortable level. We are entering 2022 in a slight stagflationary environment, one that has not been seen or traded by the majority of traders that now exist in the market.</p>\n<p>At the moment, there is still net liquidity being added to the market, and that could be one of the main reasons why the S&P 500 will hold up well here, but one wonders whether it can hold these levels in Q1 when fed balance sheet stops increasing altogether. Perhaps it is time for investors to stop focusing on Meme stocks or bankrupt stocks trying \"to make a quick buck\", squeezing out shorts via buying upside calls. Perhaps the market will return to some sort of rational behavior and display some economics 101 characteristics. One thing is for sure, asset allocation will need to shift into assets that are more inflation protected, hard assets like precious metals. Will 2022 finally be the year for gold?</p>","source":"lsy1619508253632","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Fed Has Created the Monster Market: What's in Store for 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Fed Has Created the Monster Market: What's in Store for 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 17:46 GMT+8 <a href=https://realmoney.thestreet.com/investing/the-fed-has-created-the-monster-market-what-s-in-store-for-2022--15869560><strong>Realmoney</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The year 2021 should be labeled as the one that confounded even the most experienced of investors. Two years after the pandemic where the global central banks flushed the market with unimaginable ...</p>\n\n<a href=\"https://realmoney.thestreet.com/investing/the-fed-has-created-the-monster-market-what-s-in-store-for-2022--15869560\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://realmoney.thestreet.com/investing/the-fed-has-created-the-monster-market-what-s-in-store-for-2022--15869560","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168664020","content_text":"The year 2021 should be labeled as the one that confounded even the most experienced of investors. Two years after the pandemic where the global central banks flushed the market with unimaginable liquidity in a short period of time to boost an economy that came to a grinding halt, one wonders why the U.S. central bank is still adding net liquidity to the market today, albeit at a slower pace. The Fed's mantra all throughout 2021 has been that \"inflation is transitory.\" But up until recently, when inflation is seen in everything from milk, coffee, rents, lumber, gas, construction, steel... to anything consumer related, even the Fed cannot use this word with a straight face. Using the word transitory loosely can still work if the horizon is anywhere from three months to two years. It seems the bond and rates markets have now forced the hand of the Fed to realize that inflation is certainly not transitory and they need to do something about it.\nThe last two years has seen an \"everything bubble.\" Whether we like to believe it or not, all asset classes have risen with the same tide that the Fed created via its liquidity injection, some just a bit more based on beta and leverage. Many fund managers can use the word \"alpha\" to justify their returns, but in short, this Fed liquidity has distorted a host of asset prices and taking some of the larger ones way beyond their own fundamental value given what real yields and rates had done. A good example is the ARK Next Generation Internet ETF (ARKW) and racy tech growth stocks, after rallying in excess of 100%+, they have all now fallen over 50%+ the past few months, when the fundamental picture has not changed.\nAnd the simple reason is that liquidity is getting less and less in the market as the Fed is slowing down its asset purchases. Most emerging markets central banks and some developed ones have started raising rates, yet the Fed is still buying up to $90B-$100B of assets each month, two years after the pandemic. This at a time when jobless claims are at lows and the economy has recovered close to pre-pandemic levels from the demand side, if not from the employment side. The Fed's target for QE was to get employment back to pre Covid levels, but that goal post is much further now as participation rate has lagged. A lot of people have permanently retired from the workforce and this is something that the Fed is realizing just now.\nThe latest FOMC meeting presided by the Fed announced that they would reduce their asset purchases even more aggressively by $30B per month instead of $15B. At this rate, the Fed will end its QE around March 2022. The bigger question now is how soon and how fast will the Fed start to raise rates? The market is pricing in about three rate hikes just in 2022 alone. If supply chain shortages persist, inflation is not expected to come down any time soon. As we enter 2022, we are entering an economy that is robust but at risk of plateauing post the liquidity induced demand surge, and with heightened inflation not seen since the 1980s! The year over year CPI rate is averaging between 6%-7% now, and it is at an alarmingly uncomfortable level. We are entering 2022 in a slight stagflationary environment, one that has not been seen or traded by the majority of traders that now exist in the market.\nAt the moment, there is still net liquidity being added to the market, and that could be one of the main reasons why the S&P 500 will hold up well here, but one wonders whether it can hold these levels in Q1 when fed balance sheet stops increasing altogether. Perhaps it is time for investors to stop focusing on Meme stocks or bankrupt stocks trying \"to make a quick buck\", squeezing out shorts via buying upside calls. Perhaps the market will return to some sort of rational behavior and display some economics 101 characteristics. One thing is for sure, asset allocation will need to shift into assets that are more inflation protected, hard assets like precious metals. Will 2022 finally be the year for gold?","news_type":1,"symbols_score_info":{".DJI":0.9,".SPX":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":2227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009952067,"gmtCreate":1640468036368,"gmtModify":1676533521748,"author":{"id":"4097303038105650","authorId":"4097303038105650","name":"JohnDee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097303038105650","authorIdStr":"4097303038105650"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009952067","repostId":"1141357068","repostType":4,"isVote":1,"tweetType":1,"viewCount":3080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009956330,"gmtCreate":1640467844680,"gmtModify":1676533521725,"author":{"id":"4097303038105650","authorId":"4097303038105650","name":"JohnDee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097303038105650","authorIdStr":"4097303038105650"},"themes":[],"htmlText":"Test","listText":"Test","text":"Test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009956330","repostId":"2193917872","repostType":4,"repost":{"id":"2193917872","kind":"highlight","pubTimestamp":1640398248,"share":"https://ttm.financial/m/news/2193917872?lang=en_US&edition=fundamental","pubTime":"2021-12-25 10:10","market":"us","language":"en","title":"3 Best Buffett Stocks to Buy for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193917872","media":"Motley Fool","summary":"Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio.","content":"<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Buffett Stocks to Buy for the Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Buffett Stocks to Buy for the Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:10 GMT+8 <a href=https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","BMY":"施贵宝","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193917872","content_text":"Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.\nThe Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.\n1. Johnson & Johnson\nThe first pharma stock within Berkshire's portfolio to contemplate purchasing is Johnson & Johnson (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.\nJ&J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.\nJ&J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&J's $69 billion in net sales.\nThese drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.\nJ&J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.\nIncome investors can scoop up J&J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.\n2. Bristol Myers Squibb\nAnother Buffett stock that could be a great fit in your portfolio is Bristol Myers Squibb (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.\nBristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with Pfizer (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.\nWhat matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.\nAs a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.\nYield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.\n3. AbbVie\nFinally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.\nIt's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.\nAbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.\nAbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3. This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.","news_type":1,"symbols_score_info":{"JNJ":0.9,"BMY":0.9,"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":2455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9009952313,"gmtCreate":1640468048467,"gmtModify":1676533521758,"author":{"id":"4097303038105650","authorId":"4097303038105650","name":"JohnDee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097303038105650","authorIdStr":"4097303038105650"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009952313","repostId":"1168664020","repostType":4,"repost":{"id":"1168664020","kind":"news","pubTimestamp":1640339173,"share":"https://ttm.financial/m/news/1168664020?lang=en_US&edition=fundamental","pubTime":"2021-12-24 17:46","market":"us","language":"en","title":"The Fed Has Created the Monster Market: What's in Store for 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1168664020","media":"Realmoney","summary":"The year 2021 should be labeled as the one that confounded even the most experienced of investors. T","content":"<p>The year 2021 should be labeled as the one that confounded even the most experienced of investors. Two years after the pandemic where the global central banks flushed the market with unimaginable liquidity in a short period of time to boost an economy that came to a grinding halt, one wonders why the U.S. central bank is still adding net liquidity to the market today, albeit at a slower pace. The Fed's mantra all throughout 2021 has been that \"inflation is transitory.\" But up until recently, when inflation is seen in everything from milk, coffee, rents, lumber, gas, construction, steel... to anything consumer related, even the Fed cannot use this word with a straight face. Using the word transitory loosely can still work if the horizon is anywhere from three months to two years. It seems the bond and rates markets have now forced the hand of the Fed to realize that inflation is certainly not transitory and they need to do something about it.</p>\n<p>The last two years has seen an \"everything bubble.\" Whether we like to believe it or not, all asset classes have risen with the same tide that the Fed created via its liquidity injection, some just a bit more based on beta and leverage. Many fund managers can use the word \"alpha\" to justify their returns, but in short, this Fed liquidity has distorted a host of asset prices and taking some of the larger ones way beyond their own fundamental value given what real yields and rates had done. A good example is the ARK Next Generation Internet ETF (ARKW) and racy tech growth stocks, after rallying in excess of 100%+, they have all now fallen over 50%+ the past few months, when the fundamental picture has not changed.</p>\n<p>And the simple reason is that liquidity is getting less and less in the market as the Fed is slowing down its asset purchases. Most emerging markets central banks and some developed ones have started raising rates, yet the Fed is still buying up to $90B-$100B of assets each month, two years after the pandemic. This at a time when jobless claims are at lows and the economy has recovered close to pre-pandemic levels from the demand side, if not from the employment side. The Fed's target for QE was to get employment back to pre Covid levels, but that goal post is much further now as participation rate has lagged. A lot of people have permanently retired from the workforce and this is something that the Fed is realizing just now.</p>\n<p>The latest FOMC meeting presided by the Fed announced that they would reduce their asset purchases even more aggressively by $30B per month instead of $15B. At this rate, the Fed will end its QE around March 2022. The bigger question now is how soon and how fast will the Fed start to raise rates? The market is pricing in about three rate hikes just in 2022 alone. If supply chain shortages persist, inflation is not expected to come down any time soon. As we enter 2022, we are entering an economy that is robust but at risk of plateauing post the liquidity induced demand surge, and with heightened inflation not seen since the 1980s! The year over year CPI rate is averaging between 6%-7% now, and it is at an alarmingly uncomfortable level. We are entering 2022 in a slight stagflationary environment, one that has not been seen or traded by the majority of traders that now exist in the market.</p>\n<p>At the moment, there is still net liquidity being added to the market, and that could be one of the main reasons why the S&P 500 will hold up well here, but one wonders whether it can hold these levels in Q1 when fed balance sheet stops increasing altogether. Perhaps it is time for investors to stop focusing on Meme stocks or bankrupt stocks trying \"to make a quick buck\", squeezing out shorts via buying upside calls. Perhaps the market will return to some sort of rational behavior and display some economics 101 characteristics. One thing is for sure, asset allocation will need to shift into assets that are more inflation protected, hard assets like precious metals. Will 2022 finally be the year for gold?</p>","source":"lsy1619508253632","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Fed Has Created the Monster Market: What's in Store for 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Fed Has Created the Monster Market: What's in Store for 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 17:46 GMT+8 <a href=https://realmoney.thestreet.com/investing/the-fed-has-created-the-monster-market-what-s-in-store-for-2022--15869560><strong>Realmoney</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The year 2021 should be labeled as the one that confounded even the most experienced of investors. Two years after the pandemic where the global central banks flushed the market with unimaginable ...</p>\n\n<a href=\"https://realmoney.thestreet.com/investing/the-fed-has-created-the-monster-market-what-s-in-store-for-2022--15869560\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://realmoney.thestreet.com/investing/the-fed-has-created-the-monster-market-what-s-in-store-for-2022--15869560","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168664020","content_text":"The year 2021 should be labeled as the one that confounded even the most experienced of investors. Two years after the pandemic where the global central banks flushed the market with unimaginable liquidity in a short period of time to boost an economy that came to a grinding halt, one wonders why the U.S. central bank is still adding net liquidity to the market today, albeit at a slower pace. The Fed's mantra all throughout 2021 has been that \"inflation is transitory.\" But up until recently, when inflation is seen in everything from milk, coffee, rents, lumber, gas, construction, steel... to anything consumer related, even the Fed cannot use this word with a straight face. Using the word transitory loosely can still work if the horizon is anywhere from three months to two years. It seems the bond and rates markets have now forced the hand of the Fed to realize that inflation is certainly not transitory and they need to do something about it.\nThe last two years has seen an \"everything bubble.\" Whether we like to believe it or not, all asset classes have risen with the same tide that the Fed created via its liquidity injection, some just a bit more based on beta and leverage. Many fund managers can use the word \"alpha\" to justify their returns, but in short, this Fed liquidity has distorted a host of asset prices and taking some of the larger ones way beyond their own fundamental value given what real yields and rates had done. A good example is the ARK Next Generation Internet ETF (ARKW) and racy tech growth stocks, after rallying in excess of 100%+, they have all now fallen over 50%+ the past few months, when the fundamental picture has not changed.\nAnd the simple reason is that liquidity is getting less and less in the market as the Fed is slowing down its asset purchases. Most emerging markets central banks and some developed ones have started raising rates, yet the Fed is still buying up to $90B-$100B of assets each month, two years after the pandemic. This at a time when jobless claims are at lows and the economy has recovered close to pre-pandemic levels from the demand side, if not from the employment side. The Fed's target for QE was to get employment back to pre Covid levels, but that goal post is much further now as participation rate has lagged. A lot of people have permanently retired from the workforce and this is something that the Fed is realizing just now.\nThe latest FOMC meeting presided by the Fed announced that they would reduce their asset purchases even more aggressively by $30B per month instead of $15B. At this rate, the Fed will end its QE around March 2022. The bigger question now is how soon and how fast will the Fed start to raise rates? The market is pricing in about three rate hikes just in 2022 alone. If supply chain shortages persist, inflation is not expected to come down any time soon. As we enter 2022, we are entering an economy that is robust but at risk of plateauing post the liquidity induced demand surge, and with heightened inflation not seen since the 1980s! The year over year CPI rate is averaging between 6%-7% now, and it is at an alarmingly uncomfortable level. We are entering 2022 in a slight stagflationary environment, one that has not been seen or traded by the majority of traders that now exist in the market.\nAt the moment, there is still net liquidity being added to the market, and that could be one of the main reasons why the S&P 500 will hold up well here, but one wonders whether it can hold these levels in Q1 when fed balance sheet stops increasing altogether. Perhaps it is time for investors to stop focusing on Meme stocks or bankrupt stocks trying \"to make a quick buck\", squeezing out shorts via buying upside calls. Perhaps the market will return to some sort of rational behavior and display some economics 101 characteristics. One thing is for sure, asset allocation will need to shift into assets that are more inflation protected, hard assets like precious metals. Will 2022 finally be the year for gold?","news_type":1,"symbols_score_info":{".DJI":0.9,".SPX":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":2227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009956330,"gmtCreate":1640467844680,"gmtModify":1676533521725,"author":{"id":"4097303038105650","authorId":"4097303038105650","name":"JohnDee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097303038105650","authorIdStr":"4097303038105650"},"themes":[],"htmlText":"Test","listText":"Test","text":"Test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009956330","repostId":"2193917872","repostType":4,"repost":{"id":"2193917872","kind":"highlight","pubTimestamp":1640398248,"share":"https://ttm.financial/m/news/2193917872?lang=en_US&edition=fundamental","pubTime":"2021-12-25 10:10","market":"us","language":"en","title":"3 Best Buffett Stocks to Buy for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193917872","media":"Motley Fool","summary":"Each of these three big pharma stocks are featured in Berkshire Hathaway's massive portfolio.","content":"<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Source Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Best Buffett Stocks to Buy for the Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Best Buffett Stocks to Buy for the Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-25 10:10 GMT+8 <a href=https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","BMY":"施贵宝","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/12/24/3-best-buffett-stocks-to-buy-for-the-long-haul/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193917872","content_text":"Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.\nThe Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors could also benefit from adding these stocks to their portfolios. Here are three healthcare stocks that Buffett owns, which you may also want to consider buying and holding for the long run.\n1. Johnson & Johnson\nThe first pharma stock within Berkshire's portfolio to contemplate purchasing is Johnson & Johnson (NYSE:JNJ). While the stock is one of Buffett's smallest holdings, valued at just under $55 million, this doesn't take away from its 59 consecutive years of dividend increases that make the stock a Dividend King.\nJ&J will be spinning off its slower-growing and less profitable consumer health segment in the next 18 to 24 months, which should allow the company to focus on its faster-growing, more profitable pharmaceutical segment.\nJ&J has a strong existing drug portfolio, which should be able to make up for the upcoming 2025 to 2026 patent expirations for its top-selling drug known, Stelara. Year to date, the immunology drug made up just 9.9% of J&J's $69 billion in net sales.\nThese drugs include the immunology blockbuster Tremfya, which received its first of three U.S. Food and Drug Administration (FDA) approvals to date in July 2017. Another drug that was recently approved by the FDA was the oncology blockbuster called Darzalex, which received its first of nine FDA approvals to date in November 2015. These two drugs have grown their year-to-date revenue at high-40% clips year over year and should remain under patent most of this decade.\nJ&J's enviable existing drug portfolio and its nearly four dozen indications in late-stage clinical trials explain why analysts anticipate that the stock will deliver 8% annual non-GAAP (adjusted) earnings per share (EPS) growth over the next five years.\nIncome investors can scoop up J&J's 2.5% dividend yield at a forward P/E ratio of just 16.2 times, which makes the steady healthcare stock a great buy for the long term.\n2. Bristol Myers Squibb\nAnother Buffett stock that could be a great fit in your portfolio is Bristol Myers Squibb (NYSE:BMY). Berkshire's Bristol Myers Squibb stake totals nearly $1.4 billion, making it one of the largest healthcare holdings in Berkshire's portfolio.\nBristol Myers Squibb's oncology blockbusters Revlimid and Opdivo and the anticoagulant blockbuster co-owned with Pfizer (NYSE:PFE) named Eliquis each face patent expirations later this decade. While looming patent expirations on three drugs that account for approximately two-thirds of your company's total revenue sounds frightening, this is nothing new; it's just the nature of Bristol Myers Squibb's industry.\nWhat matters most is that a company is proactive in developing and acquiring its next generation of blockbuster drugs to absorb key patent expirations. With more than 50 compounds in over 40 different disease areas currently in development at Bristol Myers Squibb, this is exactly what the company has been doing for years now.\nAs a result, analysts are projecting that Bristol Myers Squibb will be able to generate 6% annual earnings growth through the next five years.\nYield-hungry investors can buy Bristol Myers Squibb's market-crushing 3.5% yield at a ridiculously cheap forward P/E ratio of 7.9, which is what makes the stock a buy for those looking to hedge against inflation.\n3. AbbVie\nFinally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE:ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock.\nIt's well known at this point that the biopharmaceutical's top-selling drug in the world, Humira, will be facing intense biosimilar competition in the U.S. beginning in 2023. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023.\nAbbVie has 54 compounds in various stages of clinical trials, which is why analysts are forecasting that the stock will grow its adjusted EPS 4.5% annually in the next five years.\nAbbVie's massive 4.4% dividend yield can be picked up at a forward P/E ratio of only 9.3. This is an attractive valuation for a stock with the ability to fight off inflation with healthy dividend hikes.","news_type":1,"symbols_score_info":{"JNJ":0.9,"BMY":0.9,"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":2455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009952067,"gmtCreate":1640468036368,"gmtModify":1676533521748,"author":{"id":"4097303038105650","authorId":"4097303038105650","name":"JohnDee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4097303038105650","authorIdStr":"4097303038105650"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009952067","repostId":"1141357068","repostType":4,"isVote":1,"tweetType":1,"viewCount":3080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
